Litifilimab Shows Durable Skin Clearance in 52-Week Lupus Data, Phase 3 Readout Expected H1 2027
BIIB sits 60% above its 52-week low of $138 on light trading volume (0.2× avg).
Summary
Biogen's litifilimab delivered 52-week Phase 2 data in cutaneous lupus erythematosus showing continued improvement: 27.2% of patients achieved clear or almost clear skin (CLA-IGA-R 0/1) at Week 52, up from 19.0% at Week 24, with a similar trend on CLASI-70 (28.8% vs 21.7%). Crossover patients who switched from placebo at Week 24 saw rapid onset of benefit within four weeks, and 33.7% reached clear/almost clear skin by Week 52. Safety remained consistent with prior studies, with serious AEs in 3.4% of participants. This is the longest dataset for litifilimab in CLE and reinforces its first-in-class potential, with Breakthrough Therapy Designation already granted in January 2026. The Phase 3 part of AMETHYST remains blinded and is expected to read out in the first half of 2027. For a $32.7B market cap company with a pipeline-heavy thesis, positive late-stage data in an indication with no approved targeted therapies is a meaningful de-risking event. The stock is trading near its 52-week high, suggesting the market may already be pricing in some pipeline optimism, but this data adds concrete evidence of durability and crossover benefit. Watch for Phase 3 results in H1 2027 as the next major catalyst.
At the time of this announcement, BIIB was trading at $221.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.7B. The 52-week trading range was $138.00 to $230.49. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.